Cell MedX Corp. Announces Full Revocation of British Columbia Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - November 27, 2023) - Cell MedX Corp. ("Cell MedX" or the "Company") (OTC Pink: CMXC)...
Year: 2023
GE HealthCare Releases MyBreastAI Suite to Support Clinicians in Accelerating Breast Cancer Detection
New offering provides an all-in-one AI platform optimized for mammography, that seamlessly integrates artificial intelligence (AI) applications from iCAD to...
Cloud DX Reports Positive Third Quarter and Year to Date 2023 Results
Highlights include 32.6% increase in YTD revenue, 52.2% increase in YTD gross profit and 47.5% improvement in Adjusted EBITDA compared...
Impact Fusion International Announces Its First Feedlot Order in Texas
NAPOLEONVILLE, LA / ACCESSWIRE / November 27, 2023 / Impact Fusion International Inc. (OTC PINK:IFUS)The Company is pleased to report...
Piper Sandler Strengthens Healthcare Investment Banking Team with the Addition of Brandon Rice
NEW YORK--(BUSINESS WIRE)--$PIPR--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of Brandon Rice...
Model N Management to Present at the Raymond James 2023 TMT and Consumer Conference
SAN MATEO, Calif.--(BUSINESS WIRE)--Model N, Inc. (NYSE: MODN), the leader in revenue optimization and compliance today announced that Model N...
Sona Nanotech Closes Private Placement Financing to Raise $750,000 in Gross Proceeds and Announces Additional Financing
Halifax, Nova Scotia--(Newsfile Corp. - November 27, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")...
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
The ICONIC program now includes four Phase 3 studies evaluating JNJ-2113; Co-primary endpoints for all four studies are PASI-90 and/or...
EchoNous and United Medical Instruments (UMI) Join Forces to Accelerate Kosmos Growth in the USA
REDMOND, WA / ACCESSWIRE / November 27, 2023 / EchoNous, a trailblazer in AI-enabled point-of-care ultrasound (POCUS) technology, is excited...
New Peer-Reviewed Study Shows That Olleyes VisuALL VRP is Comparable to HVF and Offers Valuable Supplement to Standard Automated Perimetry for Pediatric Patients
Study completed at Duke University shows that the VisuALL is suitable substitute for HVF when testing pediatric patients.SUMMIT, NJ /...
Blue Sky Specialty Pharmacy New Partnership With UCB’s Bimzelx(R) (Bimekizumab-Bkzx)
MOUNT PLEASANT, SC / ACCESSWIRE / November 27, 2023 / Blue Sky Specialty Pharmacy, a prominent provider of comprehensive specialty...
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia
ZURICH, SWITZERLAND / ACCESSWIRE / November 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss...
Glioblastoma Foundation Hosts ‘Rock Against Glioblastoma’ (RAG), Shining a Spotlight on Deadliest Form of Brain Cancer
First Annual Music Festival Features Talented Lineup of Performers at the Legendary Cat's Cradle, Raising Vital Funds for Glioblastoma Research...
Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)
Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerabilityCompany expects to engage FDA...
FSD Pharma Inc. Obtains Final Order for Plan of Arrangement
TORONTO, ON / ACCESSWIRE / November 27, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
Clearmind Medicine CEO, Dr. Adi Zuloff-Shani, and MAPS founder and psychedelic sector pioneer, Rick Doblin, will discuss the growing and...
ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease
MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for...
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
MitoCareX Bio has met its second milestone as part of its joint venture agreement with the Company TEL AVIV, Israel,...
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end...
Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesNew...